COVID vaccine recommendations in dermatologic patients on immunosuppressive agents: Lessons learned from pandemic.
J Cosmet Dermatol
; 2022 Oct 10.
Article
in English
| MEDLINE | ID: covidwho-2063826
ABSTRACT
Since SARS-CoV2 vaccines were approved without enough long-term monitoring due to emergent situations, some issues have been raised about timing and protocol of receiving them by patients treated by different immunosuppressive agents. Here, we present different aspects of SARS-CoV-2 vaccination in such patients in the field of dermatology. In brief, SARS-CoV-2 vaccination is recommended in all dermatologic patients, regardless of their disorders and therapeutic regimens. Nevertheless, special considerations should be given to the immunosuppressive therapy and its association with vaccination timing due to the decreased immunogenicity of vaccines in this setting. Novel biologic immunotherapies are advantageous over conventional systemic therapies not only in their safety and selective functions but also in this aspect that many of them do not affect vaccines immunogenicity.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Topics:
Vaccines
Language:
English
Journal subject:
Dermatology
Year:
2022
Document Type:
Article
Affiliation country:
Jocd.15448
Similar
MEDLINE
...
LILACS
LIS